Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the delivery of a cannabis shipment worth approximately C$10 million - the company's largest ever shipment to Israel, and what is believed to be the largest export of medical Cannabis into the Israeli market. Delivered in December, the shipment will be recognized as revenue in Aurora's FY22 Q2 period

On Thursday a case was filed in the Eastern District of Virginia by investor Michelle DeLuca as a class action against Instadose Pharma Corporation and its CEO Terry Wiltshire. The case alleges that false filings and other documents resulted in securities violations.

The complaint explained that corporation was originally known as Mikrocoze Inc. and was focused on selling furniture for small spaces. After the resignation of the then-treasurer, the corporation participated in a “Business Combination” merger under Canadian law with Instadose Canada, a corporation that focuses on selling pharmaceutical grade agricultural products including cannabis.

It seems the losing streak continues for the Canadian Cannabis LP Index for the sixth month now, after declining 13.5% in December to 194.95, New Cannabis Ventures writes. (Click for Benzinga article)

After a 1% gain in June, the index retreated nearly 27% in the third quarter.

The index, which fell 30.1% in 2020 to end at 275.16, dropped 26% in the fourth quarter and 29.2% for all of 2021.

In addition, it remains considerably below the all-time closing high of 1314.33 in September 2018. A new multi-year closing low of 196.10 was recorded in March 2020.

For Canadian cannabis investors, 2021 was a rollercoaster ride of a year driven largely by wild swings in expectations for federal legalization south of the border, and plunging recreational pot prices at home that continue to test the financial resilience of producers. 

At the same time, Canada's pot firms are anxiously awaiting Ottawa's three-year review of its industry-defining legislation. But the Health Minister's deadline to table findings and recommendations in the House of Commons and Senate isn't until early 2023.

With yet another year of uncertainty on the horizon, Yahoo Finance Canada spoke to three industry stakeholders about the trends they see shaping the sector, and what's on their wishlist of policy changes from Ottawa.

Next month, Aurora Cannabis Inc. (TSX: ACB) (Nasdaq: ACB) will release fourth quarter financial results and we expect the market to be highly focused on the numbers that are reported and any forward looking guidance from the management team.

In the prior quarter, the Canadian Licensed Producer reported positive earnings per share (EPS) which surprised us. The positive EPS in the third quarter follows a few quarters of Aurora Cannabis recording negative EPS that also came in lower than what analysts expected.  (Raed full article here)

The study reviewed Alberta and Ontario emergency department data.

The figures represent a 35 per cent increase in year-over-year sales nationwide.

Canadians spent more than $364 million on retail cannabis products in the month of October, according to the latest figures from Statistics Canada.

Health Canada has issued a warning over “copycat” cannabis edibles that closely resemble popular candies and snack foods, saying it is aware of several instances of children being hospitalized after consuming the illegal products.

The warning, issued Wednesday, mentions several unregulated cannabis products with flashy packaging, pictures and catchy names or symbols that mimic popular brands such as “Stoneo,” packaged to look like Oreo cookies, or “Medicated Sour” Skittles packaged to look like the popular candy.

“Examples of copycat illegal edible cannabis can include cereal and snack foods such as chips, cheese puffs, cookies, chocolate bars, and a variety of popular candies in colourful packaging,” reads the warning.

Cannabis stocks like Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) and Tilray Inc. (TSX:TLRY)(NASDAQ:TLRY) still hold nice growth potential.

Cannabis stocks were outstanding vehicles for growth following the 2015 Canadian federal election. Justin Trudeau’s Liberals fulfilled their big legislative promise and legalized recreational cannabis across Canada. That came into effect on October 2018. Since then, cannabis stocks have been a disappointing headache. Today, I want to look at two cannabis stocks that could buck this trend in 2022. Should investors have faith in this struggling sector? Let’s find out.

Three years ago when Canada legalized recreational weed and investors’ enthusiasm was higher than a weed party, a Bizworld column pointed out the pitfalls of investing in marijuana stocks.

Canada’s 17 marijuana stocks were overvalued at $3.5 billion with a mere $30 million total sales. None were profitable.

Not much has changed in the profit ledger.

The top 11 as selected by Investopdia and Cantechletter have increased sales but still bleed red ink like an atmospheric river.

Between them these companies are on track for $3.7 billion sales in the current fiscal year with losses of $3.9 billion. Hardly inviting to investors.

Together they have accumulated deficits of $2.25 billion since starting.